Overview

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Status:
Active, not recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. - Paclitaxel (also called Taxol) - Doxorubicin also called Adriamycin - Cyclophosphamide, also called Cytoxan

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Incyte Corporation

Treatments:

Albumin-Bound Paclitaxel
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Paclitaxel